<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523366</url>
  </required_header>
  <id_info>
    <org_study_id>D5130L00012</org_study_id>
    <nct_id>NCT01523366</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study With Ticagrelor in Hispanic Patients</brief_title>
  <official_title>A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic
      patients with stable coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet
      Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery
      Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose</measure>
    <time_frame>At 2 hours after the loading dose</time_frame>
    <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose</measure>
    <time_frame>At 0.5 and 8 hours after the loading dose</time_frame>
    <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8</measure>
    <time_frame>At 2 hours and 8 hours on Day 7 after multiple doses, and at the end of dosing interval on Day 8</time_frame>
    <description>The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses</measure>
    <time_frame>Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose</time_frame>
    <description>The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses</measure>
    <time_frame>Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose</time_frame>
    <description>The SD is a statistic using the log-transformed data and is not the geometric SD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Min - 90mg/Max - 180mg tablets (loading dose)</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg (once daily)/Max - 600mg tablets (loading dose)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures

          -  Male or female patients aged 18 years or older Documented stable CAD fulfilling and
             taking 75-100mg ASA daily treatment

          -  Females must be post menopausal or surgically sterile Self-identified as Hispanic

        Exclusion Criteria:

          -  Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or
             prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel,
             ASA dose other than 75 to 100 mg daily) during study period

          -  Patients who had ACS or stent placed within 12 months of screening Patients with a
             history of moderate or severe hepatic impairment

          -  Current smokers, including the use of tobacco containing products in the past 1 month
             of randomization

          -  Patients requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Carlson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca PharmaceuticalsRoom C3B-718PO Box 15437Wilmington, DE 19850-5437 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=484&amp;filename=D5130L00012_Clinical_Study_Protocol_Redacted_4-9-14_Redacted.pdf</url>
    <description>D5130L00012_Clinical_Study_Protocol_Redacted</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=484&amp;filename=D5130L00012_CSR_Synopsis_01Apr2014.pdf</url>
    <description>CSR_Synopsis</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <results_first_submitted>May 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2014</results_first_posted>
  <last_update_submitted>August 14, 2014</last_update_submitted>
  <last_update_submitted_qc>August 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable Coronary Artery Disease, CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from 6 centers in the United States from April 2012 until May 2013.</recruitment_details>
      <pre_assignment_details>53 patients screened; 40 patients randomized; 38 patients completed the study (7, 8, or 9 days of both treatment sequences), and 39 completed follow-up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence</title>
          <description>Ticagrelor 180 milligrams (mg) loading dose followed by 90 mg twice daily (bd) for 7,8 or 9 days (Period 1), and then clopidogrel 600 mg loading dose followed by 75 mg once daily (od) for 7, 8 or 9 days (Period 2).</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days (Period 1), then ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days (Period 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period - 10-14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not completed at least 7 days treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Analysis Set for demography (N=40) - included all patients who signed informed consent and were randomized into the study. Pharmacodynamic (PD) Analysis Set for outcomes (N=38) - included all patients for whom PD data was available with no major protocol deviations thought to significantly affect the PD of ticagrelor or clopidogrel</population>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence</title>
          <description>Ticagrelor 180 milligrams (mg) loading dose followed by 90 mg twice daily (bd) for 7,8 or 9 days (Period 1), and then clopidogrel 600 mg loading dose followed by 75 mg once daily (od) for 7, 8 or 9 days (Period 2).</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days (Period 1), then ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days (Period 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose</title>
        <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
        <time_frame>At 2 hours after the loading dose</time_frame>
        <population>Pharmacodynamic (PD) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Arm</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Arm</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose</title>
          <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
          <population>Pharmacodynamic (PD) Analysis Set</population>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="12.4" upper_limit="55.9"/>
                    <measurement group_id="O2" value="201.4" lower_limit="178.7" upper_limit="224.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-167.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-197.0</ci_lower_limit>
            <ci_upper_limit>-137.4</ci_upper_limit>
            <estimate_desc>Ticagrelor minus clopidogrel</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose</title>
        <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
        <time_frame>At 0.5 and 8 hours after the loading dose</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Arm</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Arm</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose</title>
          <description>Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
          <population>PD Analysis Set</population>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.6" lower_limit="105.1" upper_limit="164.1"/>
                    <measurement group_id="O2" value="269.8" lower_limit="238.7" upper_limit="300.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="9.2" upper_limit="58.8"/>
                    <measurement group_id="O2" value="202.8" lower_limit="176.6" upper_limit="229.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 0.5 hours after the loading dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-135.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-172.3</ci_lower_limit>
            <ci_upper_limit>-98.0</ci_upper_limit>
            <estimate_desc>Ticagrelor minus Clopidogrel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 8 hours after the loading dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-168.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-204.0</ci_lower_limit>
            <ci_upper_limit>-133.7</ci_upper_limit>
            <estimate_desc>Ticagrelor minus Clopidogrel</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8</title>
        <description>The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
        <time_frame>At 2 hours and 8 hours on Day 7 after multiple doses, and at the end of dosing interval on Day 8</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Arm</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Arm</title>
            <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8</title>
          <description>The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (&lt;150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value</description>
          <population>PD Analysis Set</population>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours on day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="8.0" upper_limit="49.0"/>
                    <measurement group_id="O2" value="179.0" lower_limit="157.7" upper_limit="200.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours on Day 7 -ticagrelor N=36 clopidogrel N=33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="17.2" upper_limit="60.3"/>
                    <measurement group_id="O2" value="178.9" lower_limit="156.5" upper_limit="201.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Dosing Interval on Day 8 - N's per 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="29.8" upper_limit="73.1"/>
                    <measurement group_id="O2" value="182.1" lower_limit="159.5" upper_limit="204.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 2 hours on Day 7 after multiple doses</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-150.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-176.9</ci_lower_limit>
            <ci_upper_limit>-124.1</ci_upper_limit>
            <estimate_desc>Ticagrelor minus Clopidogrel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 8 hours on Day 7 after multiple doses</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-140.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-168.4</ci_lower_limit>
            <ci_upper_limit>-111.9</ci_upper_limit>
            <estimate_desc>Ticagrelor minus clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at end of dosing interval on Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model contained treatment group, period, and sequence as fixed effects, and a random effect for participant within sequence</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-130.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-158.0</ci_lower_limit>
            <ci_upper_limit>-103.2</ci_upper_limit>
            <estimate_desc>Ticagrelor minus clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses</title>
        <description>The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.</description>
        <time_frame>Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set, defined as all participants for whom at least one valid PK reading was available</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor (Treatment Period 1)</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7, 8 or 9 days</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor (Treatment Period 2)</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7, 8 or 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses</title>
          <description>The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.</description>
          <population>Pharmacokinetic (PK) Analysis Set, defined as all participants for whom at least one valid PK reading was available</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (0 hours - pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.5"/>
                    <measurement group_id="O2" value="1.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0,.5 hours after the loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.7" spread="413.1"/>
                    <measurement group_id="O2" value="118.6" spread="352.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after the loading dose - Period 2 N=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="665.4" spread="566.2"/>
                    <measurement group_id="O2" value="758.5" spread="716.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after the loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.9" spread="378.8"/>
                    <measurement group_id="O2" value="479.6" spread="210.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.8" spread="238.9"/>
                    <measurement group_id="O2" value="220.1" spread="295.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609.3" spread="271.3"/>
                    <measurement group_id="O2" value="466.5" spread="534.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.4" spread="283.8"/>
                    <measurement group_id="O2" value="305.2" spread="301.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of dosing interval on Day 8 - Period 1 N=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.3" spread="438.1"/>
                    <measurement group_id="O2" value="200.7" spread="268.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses</title>
        <description>The SD is a statistic using the log-transformed data and is not the geometric SD.</description>
        <time_frame>Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor (Treatment Period 1)</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7, 8 or 9 days</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor (Treatment Period 2)</title>
            <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7, 8 or 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses</title>
          <description>The SD is a statistic using the log-transformed data and is not the geometric SD.</description>
          <population>PK Analysis Set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (0 hours - pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0,.5 hours after the loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="66.3"/>
                    <measurement group_id="O2" value="9.3" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after the loading dose - Period 2 N=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.2" spread="128.6"/>
                    <measurement group_id="O2" value="170.8" spread="156.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after the loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.8" spread="54.6"/>
                    <measurement group_id="O2" value="97.7" spread="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.3" spread="102.1"/>
                    <measurement group_id="O2" value="62.7" spread="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.4" spread="120.8"/>
                    <measurement group_id="O2" value="97.4" spread="147.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after multiple doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.8" spread="61.9"/>
                    <measurement group_id="O2" value="83.5" spread="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of dosing interval on Day 8 - Period 1 N=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="56.6"/>
                    <measurement group_id="O2" value="57.7" spread="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of signature of the informed consent throughout the treatment period including the follow up visit (approximately 11 weeks for each participant).</time_frame>
      <desc>Adverse events were solicited at each scheduled visit and could be reported by the participant at any time during the study. When summarizing Treatment Period 1 and Treatment Period 2 totals, each participant was counted only once for an individual adverse event, regardless of whether it occurred on ticagrelor, clopidogrel or both.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor Arm</title>
          <description>Ticagrelor 180 mg loading dose followed by 90 mg bd for 7,8 or 9 days.</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel Arm</title>
          <description>Clopidogrel 600 mg loading dose followed by 75 mg od for 7, 8 or 9 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of the submission for publication. The Investigators in the Multi-Center (MC) study agree to postpone MC publications until the earlier of the first AZ-authorized publication or up to 18 months from study completion at all sites.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Total N for the secondary outcome analysis after multiple doses and for PK measures was not the same for 2 hours, 8 hours and end of dosing. Only the first time point total N can be reported via the form. Row titles indicate N's where they differ.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tomas LG Andersson, MD, PhD</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-800-236-9933</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

